





JOINT TRANSNATIONAL CALL 2017: "Translational Research on Rare Cancers"

PARTNER REQUEST/COLLABORATION OFFER

If you would like to have your profile published on the TRANSCAN-2 website, "Looking for a research partner" webpage, please fill out this form and send it to 

If you have any questions about this form, please do not hesitate to contact us at 

Note: Fields marked with a * are mandatory

| Contact Information | |
|----------------------------|----------------------------------|
| First name * | Frank |
| Last name * | Kischkel |
| Position * | Managing Director |
| Telephone number | 06221-8936-210 |
| E-mail address* | frank.kischkel@therapysselect.de |
| Website address | http://www.therapysselect.de |
| Institution/Organisation * | TherapySelect Dr. Frank Kischkel |
| Department* | TherapySelect Dr. Frank Kischkel |
| Street | Carl-Bosch-Straße 4 |
| Postal Code / City * | 69115 Heidelberg |
| Country * | Germany |

*** I agree with the publication of my contact data and of this form on the TRANSCAN-2 Website:**

YES



SEARCH FOR A COLLABORATOR

IF YOU ARE LOOKING FOR A PARTNER IN YOUR SUGGESTED PROPOSAL, PLEASE SPECIFY ALSO THE NEEDED EXPERTISE

| Project proposal |
|--|
| Project title (draft): |
| Short description of the project in preparation and of the consortium; description of the areas of expertise needed (Max. 2000 words): |



OFFER FOR COLLABORATION

IF YOU PROPOSE YOURSELF AS A PARTNER IN A CONSORTIUM, PLEASE DETAIL YOUR EXPERTISE

Short description of the areas of interest and expertise (Max. 2000 words):

One huge problem in cancer therapy are dramatically low response rates for chemotherapies. The success of such a therapy can be improved by testing the efficacy of chemotherapeutics before therapy is applied. TherapySelect Dr. Frank Kischkel is a small company located in Heidelberg, Germany and we offer the CTR-Test (Chemotherapy-Response-Test). This test is a commercially available diagnostic technology which is able to measure the efficacy of chemotherapeutics before a therapy is applied to find the best chemotherapy option for an individual cancer patient. The CTR-test uses living 3D microtumor structures (spheroids) from cancer patients. Freshly isolated living tumor tissue containing cells in 3D microtumors from individual patients is transported to our laboratory and the tissue is processed to isolate the spheroids. These spheroids are incubated with corresponding chemotherapeutics and the efficacy of the chemotherapeutics is determined before start of a therapy. The CTR-Test can be used to assist patients and treating physicians in therapy planning.

Especially for rare cancers, where no guidelines exist, it could be of benefit for patients to test the efficacy of several chemotherapeutics before a therapy is applied. This could help to find an effective therapy and to cure more patients with rare cancers.

In general all drugs (also targeted drugs) that directly act on cancer cells can be measured with our test system. However for the commercial use only chemotherapeutics are validated until now.

At the moment our test system still uses a radioactive tracer. But we recently received a grant from EIT Health to replace the radioactive by a non-radioactive test version. The non-radioactive version should be available at the beginning of next year.

We offer expertise in isolation of spheroids from patient tumor tissue and in efficacy testing of chemotherapeutics.

We are looking for a collaboration as partner in a forming consortium in the area of rare cancers and efficacy testing of cancer drugs. These drugs can be already established drugs in our test system (chemotherapeutics) or to be validated drugs (like targeted drugs).

Recent publications:

- **Kischkel FC**, Eich J, Meyer CI, Weidemüller P, Krapfl J, Yassin-Kelepir R, Job L, Fraefel M, Braicu I, Kopp-Schneider A, Sehouli J, De Wilde RL. New in vitro system to predict chemotherapeutic efficacy of drug combinations in fresh tumor samples. PeerJ. 2017;5:e3030.
- **Kischkel FC**, Meyer C, Eich J, Nassir M, Mentze M, Braicu I, Kopp-Schneider A, Sehouli J. Prediction of clinical response to drugs in ovarian cancer using the chemotherapy resistance test (CTR-Test). Journal of Ovarian Research 2017; 10:72.

